Healthcare M&A Trends 2026: Consolidation Continues

Healthcare is the single largest M&A sector in our database by a wide margin. Our dataset tracks 5,929+ healthcare transactions spanning physician practices, dental, veterinary, behavioral health, home health, healthcare IT, and dozens of specialty verticals. And the pace isn't slowing down. If anything, it's accelerating across sub-sectors that weren't even on most buyers' radar five years ago.

I've spent the better part of two decades advising healthcare practice owners on exits, and what I'm seeing in 2026 is a market that rewards preparation more than ever. The buyers are more sophisticated, the regulatory environment is more complex, and the spread between a well-prepared seller and an unprepared one has never been wider. Let me break down what's happening across the major healthcare M&A verticals.

Physician Practice Management Roll-Ups: The Playbook Has Matured

The physician practice management (PPM) model that started in dermatology and ophthalmology has now spread to virtually every specialty with high procedure volumes and favorable payer economics. Gastroenterology, orthopedics, urology, cardiology, and pain management are all seeing active platform-building from PE sponsors.

The playbook is well-established at this point. A PE firm backs a management company, acquires a "platform" practice at 10-14x EBITDA, then bolts on smaller practices at 5-8x. The arbitrage between add-on multiples and the eventual exit multiple drives returns. Dermatology pioneered this with firms like U.S. Dermatology Partners and Schweiger Dermatology, and the model has been replicated across specialties.

What's changing in 2026 is that the easy roll-ups have been done. In dermatology specifically, many of the attractive independent practices have already been acquired. The remaining independents tend to be smaller, more rural, or led by physicians who have already turned down offers. This is pushing PE buyers into newer specialties where consolidation is earlier-stage and the opportunity set is larger.

GI is the current darling.Gastroenterology practices with their own ambulatory surgery centers (ASCs) are commanding premium multiples because the ASC adds a high-margin procedural revenue stream. A GI practice doing $3M in collections with a profitable ASC is a very different asset than a referral-dependent internal medicine group at the same revenue. I've seen GI platform deals close at 12-14x EBITDA when the ASC economics are strong.

Orthopedics is heating up for similar reasons — high procedure volumes, ASC synergies, and favorable demographics as the population ages. The challenge is that orthopedic surgeons tend to earn very high compensation, which compresses EBITDA and makes the math harder for buyers paying on earnings multiples.

Behavioral Health: The Explosion Continues

If I had to pick one healthcare sub-sector that has transformed most dramatically in the past five years, it's behavioral health. ABA therapy (Applied Behavior Analysis) for autism, substance abuse treatment, and outpatient mental health have all gone from fragmented cottage industries to active PE targets.

ABA therapy has been the biggest story. The combination of rising autism diagnosis rates, insurance mandate coverage in all 50 states, and a highly fragmented provider landscape created the perfect conditions for consolidation. Platform ABA companies have attracted enormous capital. The challenge now is workforce — BCBAs (Board Certified Behavior Analysts) are in critically short supply, and labor costs are the primary constraint on growth and margins.

Substance abuse treatment facilities have attracted significant PE interest, though the sector has matured past its Wild West phase. The operators that survived the regulatory tightening around patient brokering and deceptive marketing are now well-positioned as legitimate platforms. Buyers are paying 6-10x EBITDA for quality operators with strong clinical outcomes data, accreditation, and diversified payer mix.

Outpatient mental health is perhaps the most interesting long-term story. Demand for therapy and psychiatric services has surged post-pandemic and hasn't come back down. Group practices with multiple therapists, psychiatrists, and a hybrid in-person/telehealth model are exactly what buyers want. The key differentiator I see in valuations is whether the practice has built a scalable clinical model or whether it's just a loose collection of solo therapists sharing overhead.

Home-Based Care: The Demographic Tailwind

Home health, hospice, and personal care services are benefiting from what may be the strongest demographic tailwind in all of healthcare. Roughly 10,000 Americans turn 65 every day, and the overwhelming preference is to age at home rather than in institutional settings. Medicare policy has reinforced this preference by shifting reimbursement toward home-based care models.

Home health agencies with Medicare certification are the most sought-after assets in this space. The Certificate of Need (CON) requirements in many states create a regulatory moat — you can't just start a new Medicare-certified home health agency in a CON state, which means existing agencies have scarcity value. I've seen CON states command 20-30% valuation premiums over non-CON states for otherwise comparable agencies.

Hospice has attracted enormous PE capital. The economics are compelling: Medicare reimburses on a per-diem basis, margins are strong for well-run operators, and demand is growing steadily. The major platforms — Amedisys, LHC Group (now part of UnitedHealth), VITAS, Kindred — have been active acquirers, and PE-backed platforms are competing aggressively for independent hospices.

Non-medical personal care (help with activities of daily living, companionship, transportation) is the most fragmented and lowest-barrier segment, but it's also seeing consolidation. The key challenge for buyers is labor — caregiver turnover rates exceeding 60% annually make it difficult to scale reliably.

Healthcare IT: Where Tech Meets Clinical

Healthcare IT sits at the intersection of technology valuations and healthcare demand — and the multiples reflect it. Our data shows healthcare IT companies trading at a median of 16.47x EBITDA, significantly above both general tech and general healthcare medians. The premium reflects high switching costs, regulatory stickiness (once a provider implements an EHR or revenue cycle management system, they rarely switch), and secular growth in healthcare digitization.

Revenue cycle management (RCM), clinical decision support, telehealth infrastructure, and healthcare data analytics are all active M&A verticals. The buyers range from large strategic acquirers (UnitedHealth's Optum, Oracle Health) to PE firms building platform plays. For SMB healthcare IT companies, the path to premium valuation runs through recurring revenue models — SaaS-based healthcare IT commands significantly higher multiples than project-based or license-based models.

The Regulatory Factor: Why Healthcare M&A Is Different

What makes healthcare M&A fundamentally different from other sectors is the regulatory overlay. Stark Law, the Anti-Kickback Statute, HIPAA, state licensure requirements, Certificate of Need laws, scope-of-practice regulations, and corporate practice of medicine (CPOM) doctrines all create complexity that doesn't exist when you're buying an HVAC company or a marketing agency.

This complexity actually benefitspractice owners in an important way: it limits the buyer pool to sophisticated, well-capitalized acquirers who can navigate the regulatory maze. These buyers tend to be less price-sensitive than individual buyers because they're building scale and can amortize compliance costs across a large platform.

CPOM doctrine is the one I get the most questions about. In many states, non-physician entities cannot directly employ physicians or own medical practices. PE firms work around this through management services organization (MSO) structures, where the PE firm owns the management company and the physician retains nominal ownership of the clinical entity. The structuring adds legal cost but doesn't prevent deals from getting done.

The regulatory environment also means that due diligence in healthcare transactions is more intensive. Buyers will scrutinize your billing practices, compliance programs, credentialing, and licensure with a level of detail that would be unusual in other industries. Having clean compliance history and proper documentation isn't just good practice — it directly impacts your valuation.

Value-Based Care vs. Fee-for-Service: The Tension Shaping Deals

The healthcare industry's ongoing shift from fee-for-service to value-based care reimbursement is creating an interesting dynamic in M&A. Practices that have successfully implemented value-based care contracts — taking on risk for patient outcomes in exchange for shared savings — are commanding premium valuations because they represent the future of healthcare economics.

But the transition is uneven and uncertain. Many practices remain predominantly fee-for-service, and buyers are unsure how quickly value-based models will scale. The result is a bifurcation: practices with demonstrated value-based care capabilities trade at a premium, while practices entirely dependent on fee-for-service revenue face questions about long-term sustainability.

For practice owners considering a sale, my practical advice is this: you don't need to fully transition to value-based care, but you should demonstrate awareness and early adoption. Participating in a few value-based contracts, tracking quality metrics, and having population health management capabilities all signal to buyers that your practice is forward-looking.

What This Means If You're Considering a Sale

The healthcare M&A market in 2026 is broadly favorable for sellers across most specialties. PE capital allocated to healthcare remains robust, strategic buyers are active, and the demographic tailwinds supporting demand for healthcare services aren't going away. But "favorable" doesn't mean "automatic."

The practices that command top-of-market valuations share common characteristics: multiple providers (reducing owner-dependence), clean financials with strong EBITDA margins, diversified payer mix, documented clinical protocols, and a physical infrastructure that doesn't require immediate capital investment. If you're thinking about selling in the next 2-3 years, the single highest-ROI activity is bringing on another provider. It simultaneously grows revenue, reduces key-person risk, and demonstrates scalability — three things every buyer wants to see.

The second highest-ROI activity is getting a realistic valuation early so you know where you stand. Too many practice owners either overestimate (based on what they heard a colleague sold for) or underestimate (based on outdated rules of thumb) their practice's value. Neither serves you well when it's time to negotiate.

Healthcare M&A consolidation isn't a cycle — it's a structural shift. The fragmented, independent practice model is giving way to organized, scaled platforms across nearly every specialty. Whether you view that as an opportunity or a threat depends largely on your timeline and preparation. For those who prepare thoughtfully, the current market offers excellent exit opportunities that may not persist indefinitely.